Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 1Phase 1/2 1Phase 1 1

Status

Active not recruiting 2Withdrawn 1Unknown 1Terminated 1Completed 1

Sponsor Class

OTHER 344INDUSTRY 297NIH 45NETWORK 6OTHER_GOV 3

Study Type

Interventional 6

Sponsor

Cancer Type

Thoracic 1Lymphoid 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Small Cell Lung Carcinoma 1Sezary Syndrome 1Ovarian Neoplasms 1Mycosis Fungoides 1Lymphoma, T-Cell, Cutaneous 1Esophageal Neoplasms 1Biliary Tract Neoplasms 1

Interventions

Radiotherapy 299Cisplatin 263Cyclophosphamide 229Doxorubicin 176Paclitaxel 166Vincristine 160Carboplatin 149Filgrastim 139Etoposide 139Gemcitabine 118Fluorouracil 113Docetaxel 112Methotrexate 106Dexamethasone 106Cytarabine 106Prednisone 91Leucovorin 90Granulocyte Colony-Stimulating Factor 74Specimen Handling 65Magnetic Resonance Spectroscopy 61Capecitabine 59Irinotecan 58Radiation 54Ifosfamide 51Oxaliplatin 48Daunorubicin 48Temozolomide 47Radiotherapy, Conformal 47Platinum 47Peripheral Blood Stem Cell Transplantation 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
NETWORK × Interventional × atezolizumab × Clear all
NCT04134000 2024-05-21

BladderGATE

Fundacion Oncosur

Phase 1 Active not recruiting
40 enrolled
Genitourinary

Urinary Bladder Neoplasms

NCT03281954 2024-04-08

Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed After Surgery by Atezolizumab or Placebo

NSABP Foundation Inc

Phase 3 Active not recruiting
1,550 enrolled
Breast

Triple Negative Breast Neoplasms

NCT03357224 2024-02-22

PARCT

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2 Terminated
26 enrolled
DermatologicLymphoid

Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous

NCT04253145 2023-11-18

Study to Assess Safety,Tolerability,Efficacy of PM01183 and Atezolizumab in Patients w/ Advanced Small Cell Lung Cancer.

Fundacion Oncosur

Phase 1/2 Unknown
184 enrolled
Thoracic

Small Cell Lung Carcinoma

NCT02659384 2023-03-14

Anti-programmed Cell Death-1 Ligand 1 (aPDL-1) Antibody Atezolizumab, Bevacizumab and Acetylsalicylic Acid in Recurrent Platinum Resistant Ovarian Cancer

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2 Completed
122 enrolled
Gynecologic

Ovarian Neoplasms

NCT03818997 2020-02-05

DYNAMIC

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2 Withdrawn
Gastrointestinal

Biliary Tract Neoplasms, Esophageal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡